Presentation is loading. Please wait.

Presentation is loading. Please wait.

New HCV reimbursement criteria

Published byCalvin Lawson Modified over 6 years ago

Similar presentations

Presentation on theme: "New HCV reimbursement criteria"— Presentation transcript:

1 New HCV reimbursement criteria 01-2017
Chronic hepatitis C with ≥ F2 fibrosis stage Chronic hepatitis C regardless of fibrosis stage if: HIV-HCV coinfection HBV-HCV coinfection Listed for or post-solid organ transplantation Listed for or post hematopoietic stem cell/bone marrow transplantation Severe extrahepatic manifestation: diffuse large cell lymphoma B, immunomediated vasculitis, renal disease related to mixed cryoglobulinemia Patient on dialysis Hemophilia or other coagulation disorder Hemoglobinopathy Pregnancy (however contra-indicated in all smpc, and IFN free combinations never tested in pregnant women): BASL recommandation is to never treat a pregnant woman

2 New HCV reimbursement criteria 01-2017
Presciption by a Specialist in Gastroenterology or Internal Medicine Attached to an academic centre if 580, 588 or 987 Attached to academic or non academic hospital if 650, 651 or 659 Training in Hepatology (15 CME/year, see details on next slide) Agrees to record follow-up data of treated patients Trough e-health plateform According to international recommandations

3 How to obtain 15 CME credits in Hepatology?
In discussion with RIZIV-INAMI This is the responsability of each prescriber to be able to demonstrate his/her credits in Hepatology

4 METAVIR F2-F3-F4 criteria consensus
(agreed at RIZIV-INAMI ) EITHER A LIVER BIOPSY, or EITHER 1 ELASTOGRAPHY TEST (cut-offs see slide 2) + 1 BIOLOGICAL FIBROSIS SCORE (cut-offs see slide 3) maximum age of lab values to be used for biological tests = 1 year results to be kept in file of patient (scores & lab values used for the test) 1 EXCEPTION: PATIENTS WITH HEMOPHILIA : * 2 BIOLOGICAL FIBROSIS SCORES CAN BE APPLIED (cut-off see above), or * 1 ELASTOGRAPHY TEST + 1 BIOLOGICAL FIBROSIS SCORE

5 chronic hepatitis C Fibroscan1
cut-offs of ELASTOGRAFY for fibrosis assesment F2-F3-F4 chronic hepatitis C (agreed at RIZIV-INAMI ) Fibroscan1 Valid if 10 correct measurements, success rate > 60%, IQR < 30% F2 ≥ 7.1 kPA F3 ≥ 9.5 kPA F4 ≥ 12.5 kPA Shear wave elastografie2 F3 ≥ 8.7 kPA F4 ≥ 10.4 kPA 3. Acoustic radiation forse impulse (ARFI, Siemens technique)3,4 F2 ≥ 1.22 m/s F3 ≥ 1,55 m/s F4 ≥ 1,80 m/s 1Castera et al. Gasteroenterology 2005 2Ferraioli et al Hepatology 2012 3Friedrich-Rust et al J Viral Hepat 2012 4Ferraioli et al J Ultrasound Med 2014

6 (agreed at RIZIV-INAMI 01.12.2016)
cut-offs of BIOLOGICAL FIBROSIS-SCORES for assesment F2-F3-F4 in chronic hepatitis C (agreed at RIZIV-INAMI ) Fibrotest (Biopredictive): Elements : α2 macroglobulin, haptoglobin, apolipoprotein A1, total bilirubin, GGT F2 : ≥ 0.49 F3: F3-F4: F4: ≥0.75 Apri (ast-platelet ratio) In a pure HCV cohort F2: APRI not to use for detection of F2 F3: ≥ 1 F4: ≥ 1.6 Reference: Holmberg, Clin Infect Dis 2013 Fib-4 (age, AST,ALT, platelets) F2 ≥ 1.45 F3: ≥ 2.1 F3-F4: ≥ 3.25 F4: ≥ 3.85 References: Vallet-Pichard, Hepatology 2007, Holmberg, Clin Infect Dis 2013, Martinez APT 2011 Useful website:

7 Update 01-2017 Genotype 1a Genotype 1b
Treatment options for antiviral therapy in Belgium Update Genotype 1a Genotype 1b Non-cirrhotic `Sofosbuvir + Daclatasvir 12 wk Ritonavir-boosted Paritaprevir + Ombitasvir + Dasabuvir + RBV 12 wk Ledipasvir/Sofosbuvir 12 wk* Velpatasvir/Sofosbuvir 12 wk Elbasvir/Grazoprevir 12 wk** *consider 8 wk if naïve and HCVRNA < IU/mL **consider 16 wk + RBV if HCVRNA> IU/mL or if baseline NS5a RAs Sofosbuvir + Simeprevir 12 wk Sofosbuvir + Daclatasvir 12 wk Ritonavir-boosted Paritaprevir + Ombitasvir 12 wk* Ledipasvir/Sofosbuvir 12 wk** Elbasvir/Grazoprevir 12 wk **consider 8 wk if naïve Cirrhotic compensated Sofosbuvir + Daclatasvir + RBV 12 wk* Ledipasvir/Sofosbuvir + RBV 12 wk* Ritonavir-boosted Paritaprevir + Ombitasvir + Dasabuvir + RBV 24 wk *In case of poor RBV tolerance, prolonge to 24 wk without RBV Sofosbuvir + Simeprevir +/- RBV 12 wk* Sofosbuvir + Daclatasvir +/- RBV 12 wk* Ritonavir-boosted Paritaprevir + Ombitasvir 12 wk Ledipasvir/Sofosbuvir +/- RBV 12 wk* PI experienced Sofosbuvir + Daclatasvir + RBV 12 wk Ledipasvir/Sofosbuvir + RBV 12 wk Velpatasvir/Sofosbuvir + RBV 12 wk Consider 24 wk + RBV in F3-F4 patients NS5a experienced Sofosbuvir + Simeprevir +RBV 24 wk* Velpatasvir + Sofosbuvir +RBV 24 wk* *based on few evidence, testing for Ras has to be considered on a case by case discussion. Alternatively, patients without an urgent need for treatment can wait until more data and/or alternative therapeutic options become available

8 Update 01-2017 Genotype 1a Genotype 1b
Treatment options for antiviral therapy in Belgium Update Genotype 1a Genotype 1b Cirrhotic decompensated Sofosbuvir + Daclatasvir + RBV 12 wk* Ledipasvir/Sofosbuvir + RBV 12 wk* Velpatasvir/Sofosbuvir + RBV 12 wk* *In case of poor RBV tolerance, prolonge to 24 wk without RBV consider treating after Tx if MELD > 18 Post-organ transplant Same recommandations than non transplanted patients RBV should be considered in all patients. However, the need for RBV in non-cirrhotic patients has not been established However, potential drug-drug interactions with immunosuppressant agents requires careful selection of agents HIV-HCV coinfected Same recommandations than monoinfected HCV patients However, potential drug-drug interactions in patients receiving antiretroviral agents requires careful selection of agents

9 Treatment options for antiviral therapy in Belgium Update 01-2017
Genotype 2 Non-cirrhotic Sofosbuvir + Velpatasvir 12 weeks Sofosbuvir + Daclatasvir 12 weeks If previous failure of Sofosbuvir + Ribavirin: Sofosbuvir + Velpatasvir or Daclatasvir + Ribavirin 12 weeks Cirrhotic compensated If previous failure of Sofosbuvir + Ribavirin: Sofosbuvir + Velpatasvir or Daclatasvir + Ribavirin 24 weeks PI experienced Not applicable NS5a experienced Sofosbuvir + Velpatasvir + Ribavirin for 24 weeks *based on few evidence, testing for Ras has to be considered on a case by case discussion. Alternatively, patients without an urgent need for treatment can wait until more data and/or alternative therapeutic options become available

10 Sofosbuvir + Velpatasvir + Ribavirin 12 weeks
Treatment options for antiviral therapy in Belgium Update Genotype 2 Cirrhotic decompensated Sofosbuvir + Velpatasvir + Ribavirin 12 weeks Sofosbuvir + Daclatasvir + Ribavirin 12 weeks *In case of poor RBV tolerance, prolonge to 24 wk without RBV consider treating after Tx if MELD > 18 Post-organ transplant Same recommendations than non transplanted patients RBV should be considered in all patients. However, the need for RBV in non-cirrhotic patients has not been established However, potential drug-drug interactions with immunosuppressant agents requires careful selection of agents HIV-HCV coinfected Same recommendations than monoinfected HCV patients However, potential drug-drug interactions in patients receiving antiretroviral agents requires careful selection of agents

11 Treatment options for antiviral therapy in Belgium Update 01-2017
Genotype 3 Non-cirrhotic Sofosbuvir + Daclatasvir 12 wk Velpatasvir/Sofosbuvir 12 wk both for treatment-experienced (IFN) or –naive patients Cirrhotic compensated Sofosbuvir + Daclatasvir + RBV 24 wk* ** Velpatasvir/Sofosbuvir 12 wk* + RBV** *treatment naive **treatment experienced (IFN) PI experienced Not applicable NS5A experienced Velpatasvir/Sofosbuvir + RBV 24 wks *based on few evidence, testing for Ras has to be considered on a case by case discussion. Alternatively, patients without an urgent need for treatment can wait until more data and/or alternative therapeutic options become available

12 Treatment options for antiviral therapy in Belgium Update 01-2017
Genotype 3 Cirrhotic decompensated Sofosbuvir + Daclatasvir + RBV 24 wk Velpatasvir/Sofosbuvir + RBV 12 wk consider treating after Tx if MELD > 18 Post-organ transplant Same recommandations than non transplanted patients RBV should be considered in all patients. However, the need for RBV in non-cirrhotic patients has not been established Potential drug-drug interactions with immunosuppressant agents requires careful selection of agents HIV-HCV coinfected Same recommandations than monoinfected HCV patients Potential drug-drug interactions in patients receiving antiretroviral agents requires careful selection of agents

13 Treatment options for antiviral therapy in Belgium Update 01-2017
Genotype 4 Non-cirrhotic Sofosbuvir + Simeprevir 12 wk Sofosbuvir + Daclatasvir 12 wk Ritonavir-boosted Paritaprevir + Ombitasvir + RBV 12 wk Ledipasvir/Sofosbuvir 12 wk Velpatasvir/Sofosbuvir 12 wk Elbasvir/Grazoprevir 12 wk Cirrhotic compensated Ledipasvir /Sofosbuvir 12 wk PI experienced Sofosbuvir + Daclatasvir + RBV 12 wk Ledipasvir/Sofosbuvir + RBV 12 wk Velpatasvir/Sofosbuvir + RBV 12 wk Consider 24 wk + RBV in F3-F4 patients NS5a experienced Sofosbuvir + Simeprevir +RBV 24 wk* Velpatasvir + Sofosbuvir +RBV 24 wk* *based on few evidence, testing for Ras has to be considered on a case by case discussion. Alternatively, patients without an urgent need for treatment can wait until more data and/or alternative therapeutic options become available

14 Treatment options for antiviral therapy in Belgium Update 01-2017
Genotype 4 Cirrhotic decompensated Sofosbuvir + Daclatasvir + RBV 12 wk* Ledipasvir/Sofosbuvir + RBV 12 wk* Velpatasvir/Sofosbuvir + RBV 12 wk* *In case of poor RBV tolerance, prolonge to 24 wk without RBV consider treating after Tx if MELD > 18 Post-organ transplant Same recommandations than non transplanted patients RBV should be considered in all patients. However, the need for RBV in non-cirrhotic patients has not been established However, potential drug-drug interactions with immunosuppressant agents requires careful selection of agents HIV-HCV coinfected Same recommandations than monoinfected HCV patients However, potential drug-drug interactions in patients receiving antiretroviral agents requires careful selection of agents

15 Update 01-2017 Genotype 5 Genotype 6
Treatment options for antiviral therapy in Belgium Update Genotype 5 Genotype 6 Non-cirrhotic Sofosbuvir+Velpatasvir 12 weeks Sofosbuvir+Ledipasvir 12 weeks Sofosbuvir+Daclatasvir 12 weeks Cirrhotic compensated PI experienced NS5a experienced Sofosbuvir+Velpatasvir+RBV 24 weeks based on few evidence, testing for Ras has to be considered on a case by case discussion. Alternatively, patients without an urgent need for treatment can wait until more data and/or alternative therapeutic options become available

16 Update 01-2017 Genotype 5 Genotype 6
Treatment options for antiviral therapy in Belgium Update Genotype 5 Genotype 6 Cirrhotic decompensated Sofosbuvir+Velpatasvir+RBV* 12 weeks Sofosbuvir+Ledipasvir+RBV* 12 weeks Sofosbuvir+Daclatasvir+RBV*12 weeks *In case of poor RBV tolerance, prolonge to 24 wk without RBV consider treating after Tx if MELD > 18 Post-organ transplant Same recommandations than non transplanted patients RBV should be considered in all patients. However, the need for RBV in non-cirrhotic patients has not been established However, potential drug-drug interactions with immunosuppressant agents requires careful selection of agents HIV-HCV coinfected Same recommandations than monoinfected HCV patients However, potential drug-drug interactions in patients receiving antiretroviral agents requires careful selection of agents

Download ppt "New HCV reimbursement criteria"

Similar presentations

Case Report Ana Carolina Cardoso

Case Report Ana Carolina Cardoso
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Phase 2 Treatment.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Phase 2 Treatment.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT-1 and HIV Coinfection NIAID ERADICATE Trial Phase 2a Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT-1 and HIV Coinfection NIAID ERADICATE Trial Phase 2a Treatment Naïve and Treatment.
HEPATITIS 2014 BC. CHRONIC HEPATITIS B THE PROBLEM 350,000,000 PEOPLE HAVE IT IT IS TRANSMITTED MOTHER TO CHILD WHERE IT IS ENDEMIC IT CAN BE TRANSMITTED.

HEPATITIS 2014 BC. CHRONIC HEPATITIS B THE PROBLEM 350,000,000 PEOPLE HAVE IT IT IS TRANSMITTED MOTHER TO CHILD WHERE IT IS ENDEMIC IT CAN BE TRANSMITTED.
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.

Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
Treatment of Chronic HCV Genotype 4

Treatment of Chronic HCV Genotype 4
OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind 18-70 years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.

OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 5 or 6 Robert G. Gish MD Staff Physician, Stanford University.

Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 5 or 6 Robert G. Gish MD Staff Physician, Stanford University.
A systematic review of hepatitis C clinical practice guidelines: Benefits, limitations and harms Lim, D., Siegel, E., Hepworth, J., Bain, T., and van Driel,

A systematic review of hepatitis C clinical practice guidelines: Benefits, limitations and harms Lim, D., Siegel, E., Hepworth, J., Bain, T., and van Driel,
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label 18-70 years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.
OBV/PTV/r Open label 18-70 years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*

OBV/PTV/r Open label years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Phase 2 Treatment.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Phase 2 Treatment.
SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.

SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.
> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.

> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.
OBV/PTV/r + DSV Open label Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 1,000 IU/ml Chronic kidney disease with eGFR < 30 ml/min/1.73m 2.

OBV/PTV/r + DSV Open label Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 1,000 IU/ml Chronic kidney disease with eGFR < 30 ml/min/1.73m 2.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.
SAPPHIRE-I Feld JJ. NEJM 2014;370:1594-1603 SAPPHIRE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for genotype 1  Treatment regimens.

SAPPHIRE-I Feld JJ. NEJM 2014;370: SAPPHIRE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for genotype 1  Treatment regimens.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in HCV Genotype 4 NIAID SYNERGY (Genotype 4) Phase 2 Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in HCV Genotype 4 NIAID SYNERGY (Genotype 4) Phase 2 Treatment Naïve and Treatment Experienced.
ELPA Symposium Compassionate Use in Hepatitis C Saving lives of patients who cannot wait Thomas Berg Section of Hepatology Clinic for Gastroenterology.

ELPA Symposium Compassionate Use in Hepatitis C Saving lives of patients who cannot wait Thomas Berg Section of Hepatology Clinic for Gastroenterology.
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology Duke University School of Medicine Durham, North Carolina Treatment of Hepatitis C in Patients.

Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology Duke University School of Medicine Durham, North Carolina Treatment of Hepatitis C in Patients.

Similar presentations

Ads by Google